Ximing Tang

7.3k citations

70 papers · 3.8k indexed · 1 hit paper · h-index 32

Molecular Biology top 5%
Oncology top 1%
Pulmonary and Respiratory Medicine top 1%
Cancer Research top 2%
Epidemiology top 10%

Co-authors: Ignacio I. Wistuba Waun Ki Hong B. Nebiyou Bekele Natalie Ozburn Diane D. Liu Marileila Varella‐Garcia César A. Moran Carmen Behrens
Topics: Lung Cancer Treatments and Mutations (28 papers)Lung Cancer Research Studies (10 papers)Lung Cancer Diagnosis and Treatment (8 papers)
Cited by: Cancer Research Oncology Pulmonary and Respiratory Medicine
Journals: Journal of Clinical Oncology PLoS ONE Cancer
Partner nations: United States China United Kingdom

In The Last Decade

Ximing Tang

70 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

KRASMutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

2007 500 citations Erminia Massarelli, Marileila Varella‐Garcia et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Ximing Tang

Since Specialization

Citations

This map shows the geographic impact of Ximing Tang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ximing Tang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ximing Tang more than expected).

Fields of papers citing papers by Ximing Tang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ximing Tang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ximing Tang. The network helps show where Ximing Tang may publish in the future.

Co-authorship network of co-authors of Ximing Tang

This figure shows the co-authorship network connecting the top 25 collaborators of Ximing Tang. A scholar is included among the top collaborators of Ximing Tang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ximing Tang. Ximing Tang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE 2025 ·Frontiers in Immunology ·(unknown),Ximing Tang,Maria Gabriela Raso,Meixian Huang,(unknown),(unknown),Christopher R. Flowers,Simrit Parmar	1
2	STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon response 2024 ·Leukemia ·Bhakti Patel,Yifan Zhou,(unknown),Feiyang Ma,Malgorzata Anna Zal,Dhiraj Kumar,Yusra B. Medik,Laura M. Kahn,(unknown),Elizabeth M. Park,Sarah Schneider,Ximing Tang,Maria Gabriela Raso,Collene Jeter,Tomasz Żal,Karen Clise-Dwyer,Khandan Keyomarsi,Filippo G. Giancotti,Simona Colla,Stephanie S. Watowich	2
3	Antitumor Activity and Biomarker Analysis for TROP2 Antibody–Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models 2024 ·Clinical Cancer Research ·Funda Meric‐Bernstam,Erkan Yuca,Kurt W. Evans,Ming Zhao,(unknown),Tsuyoshi Karibe,Maria Gabriela Raso,Ximing Tang,(unknown),(unknown),Argun Akçakanat,(unknown),(unknown),Lauren A. Byers,Debu Tripathy,(unknown),Senthil Damodaran	7
4	A photoelectrochemical immunosensing platform for ultrasensitive detection of alpha-fetoprotein based on a signal amplification strategy 2022 ·Bioelectrochemistry ·Ximing Tang,Haiwei Wang,(unknown),(unknown),(unknown),Longshan Zhao	12
5	Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer 2018 ·Clinical Cancer Research ·Yang Xie,Wei Lü,Shidan Wang,Ximing Tang,Hao Tang,Yunyun Zhou,César A. Moran,Carmen Behrens,Jack A. Roth,Qinghua Zhou,David H. Johnson,Stephen G. Swisher,John V. Heymach,Vassiliki A. Papadimitrakopoulou,Guanghua Xiao,John D. Minna,Ignacio I. Wistuba	13
6	JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer 2017 ·Molecular Cancer Therapeutics ·Kazuhiko Shien,Vassiliki A. Papadimitrakopoulou,(unknown),Carmen Behrens,Li Shen,Neda Kalhor,Juhee Song,J. Jack Lee,Jing Wang,Ximing Tang,Roy S. Herbst,Shinichi Toyooka,Luc Girard,John D. Minna,Jonathan M. Kurie,Ignacio I. Wistuba,Julie Izzo	84
7	An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2 2015 ·Clinical Cancer Research ·Robert J. Cardnell,Carmen Behrens,Lixia Diao,You-Hong Fan,Ximing Tang,Pan Tong,John D. Minna,Gordon B. Mills,John V. Heymach,Ignacio I. Wistuba,Jing Wang,Lauren A. Byers	37
8	KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib 2015 ·Clinical Cancer Research ·Monique B. Nilsson,Uma Giri,Jayanthi Gudikote,Ximing Tang,Wei Lü,Hai T. Tran,You-Hong Fan,Andrew B. Koo,Lixia Diao,Pan Tong,Jing Wang,Roy S. Herbst,Bruce E. Johnson,Andy Ryan,Alan Webster,Philip Rowe,Ignacio I. Wistuba,John V. Heymach	10
9	Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma 2013 ·Clinical Cancer Research ·Marie Cumberbatch,Ximing Tang,Garry Beran,(unknown),Xin Wang,Rebecca Ellston,Simon Dearden,Sabina Cosulich,Paul D. Smith,Carmen Behrens,Edward S. Kim,Xinying Su,Shuqiong Fan,Neil Gray,David P. Blowers,Ignacio I. Wistuba,Chris Womack	22
10	EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non–Small Cell Lung Carcinoma 2013 ·Clinical Cancer Research ·Carmen Behrens,Luisa M. Solis,Heather Lin,Ping Yuan,Ximing Tang,Humam Kadara,Erick Riquelme,Héctor Galindo,César A. Moran,Neda Kalhor,Stephen G. Swisher,George R. Simon,David J. Stewart,J. Jack Lee,Ignacio I. Wistuba	123
11	Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial 2013 ·Journal of Thoracic Oncology ·Anne S. Tsao,Suyu Liu,J. Jack Lee,Christine Alden,George R. Blumenschein,Roy S. Herbst,Suzanne E. Davis,Edward Kim,Scott M. Lippman,John V. Heymach,Hai T. Tran,Ximing Tang,Ignacio I. Wistuba,Waun Ki Hong	19
12	A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck 2012 ·Clinical Cancer Research ·Carol M. Lewis,Bonnie S. Glisson,Lei Feng,Fiona Wan,Ximing Tang,Ignacio I. Wistuba,Adel K. El‐Naggar,David I. Rosenthal,Mark S. Chambers,Robert A. Lustig,Randal S. Weber	131
13	Abnormalities of the TITF-1 Lineage-Specific Oncogene in NSCLC: Implications in Lung Cancer Pathogenesis and Prognosis 2011 ·Clinical Cancer Research ·Ximing Tang,Humam Kadara,Carmen Behrens,Diane D. Liu,Yun Xiao,David C. Rice,Adi F. Gazdar,Junya Fujimoto,César A. Moran,Marileila Varella‐Garcia,J. Jack Lee,Waun Ki Hong,Ignacio I. Wistuba	59
14	Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients with Non–Small-Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy 2011 ·Cancer Research ·Fei Yang,Ximing Tang,Erick Riquelme,Carmen Behrens,Monique B. Nilsson,Uma Giri,Marileila Varella‐Garcia,Lauren A. Byers,Heather Lin,Jing Wang,Maria Gabriela Raso,Luc Girard,Kevin R. Coombes,J. Jack Lee,Roy S. Herbst,John D. Minna,John V. Heymach,Ignacio I. Wistuba	51
15	Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome 2011 ·Cancer ·Luisa M. Solis,Carmen Behrens,Maria Gabriela Raso,Heather Lin,Humam Kadara,Ping Yuan,Héctor Galindo,Ximing Tang,J. Jack Lee,Neda Kalhor,Ignacio I. Wistuba,César A. Moran	85
16	Biological Activity of Celecoxib in the Bronchial Epithelium of Current and Former Smokers 2010 ·Cancer Prevention Research ·Edward S. Kim,Waun Ki Hong,J. Jack Lee,Li Mao,Rodolfo C. Morice,Diane D. Liu,Carlos A. Jiménez,Georgie A. Eapen,Reuben Lotan,Ximing Tang,Robert A. Newman,Ignacio I. Wistuba,Jonathan M. Kurie	39
17	Immunohistochemical Expression of Estrogen and Progesterone Receptors Identifies a Subset of NSCLCs and Correlates with EGFR Mutation 2009 ·Clinical Cancer Research ·Maria Gabriela Raso,Carmen Behrens,Matthew H. Herynk,Suyu Liu,Ludmila Prudkin,Natalie Ozburn,Denise M. Woods,Ximing Tang,Reza J. Mehran,César A. Moran,J. Jack Lee,Ignacio I. Wistuba	134
18	Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells 2009 ·PLoS ONE ·Junichi Soh,Naoki Okumura,William W. Lockwood,Hiromasa Yamamoto,Hisayuki Shigematsu,Wei Zhang,Raj Chari,David S. Shames,Ximing Tang,Calum MacAulay,Marileila Varella‐Garcia,Tõnu Vooder,Ignacio I. Wistuba,Stephen Lam,Rolf A. Brekken,Shinichi Toyooka,John D. Minna,Wan L. Lam,Adi F. Gazdar	179
19	Epidermal Growth Factor Receptor Abnormalities in the Pathogenesis and Progression of Lung Adenocarcinomas 2008 ·Cancer Prevention Research ·Ximing Tang,Marileila Varella‐Garcia,Ana C. Xavier,Erminia Massarelli,Natalie Ozburn,César A. Moran,Ignacio I. Wistuba	71
20	Loss of Fhit expression is a predictor of poor outcome in tongue cancer. 2001 ·PubMed ·Janet I. Lee,Jean‐Charles Soria,Khaled A. Hassan,Diane Liu,Ximing Tang,Adel K. El‐Naggar,Waun Ki Hong,Mao Li	44

About Ximing Tang

Ximing Tang is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 70 papers that have together received 3.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Research Studies (10 papers) and Lung Cancer Diagnosis and Treatment (8 papers). The work is most often cited by research in Cancer Research (1.0k citations), Oncology (1.7k citations) and Pulmonary and Respiratory Medicine (1.6k citations). Ximing Tang has collaborated with scholars based in United States, China and United Kingdom. Frequent co-authors include Ignacio I. Wistuba, Waun Ki Hong, B. Nebiyou Bekele, Natalie Ozburn, Diane D. Liu, Marileila Varella‐Garcia, César A. Moran, Carmen Behrens, John D. Minna and Roy S. Herbst. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact